HEALTH● LOWAug 12 · Aug 12, 2026, 11:29 AM
Neurocrine slips as safety issues linked to Vykat XR resurface
Seeking Alpha Tech
Neurocrine's stock has declined due to resurfacing safety issues associated with its drug, Vykat XR. This indicates potential concerns for both the company's performance and patient health.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH38m agoPope doing physical therapy, good recovery of lung that was operated onANSA [en]HEALTH39m agoPope doing physical therapy, good recovery of the operated lungANSA [en]HEALTH1h agoWHO boosts preparedness for Ebola-related virus in 3 countriesVanguard NigeriaHEALTH2h agoNAFDAC records 213 raids, 474 new cases in eight monthsPremium Times